Recursion Pharmaceuticals Shares Plunge 8.06% as ARK Invest Adds Stake
Recursion Pharmaceuticals shares dropped 8.06% to close at $3.42, underperforming the S&P 500’s 0.69% gain. ARK Invest bought Recursion shares after Nvidia exited its stake, alongside a $24 million Figma purchase ahead of Feb 25 earnings projected at $25.5 million revenue and -$0.28 EPS.
1. One-Day Stock Decline
Shares of Recursion Pharmaceuticals dropped 8.06% to $3.42 in the latest session, underperforming the S&P 500’s 0.69% gain, Dow’s 0.47% rise and Nasdaq’s 0.9% advance. Year-to-date the stock is down 25%, lagging the Medical sector’s 0.77% gain.
2. Nvidia Exit and ARK Invest Purchase
ARK Invest added Recursion shares following Nvidia’s fourth-quarter exit from its stake, highlighting renewed institutional interest despite recent underperformance. The purchase coincided with ARK’s $24 million investment in Figma shares.
3. Upcoming Earnings Forecast
The company is set to report Q4 and full-year results on February 25 with consensus estimates of -$0.28 EPS (47% improvement) and $25.5 million revenue (460% year-over-year growth). Full-year forecasts call for -$1.59 EPS and $64.62 million revenue, up 9.8%.